- Details
- Alicia Morgans and Nima Sharifi discuss the role of the HSD3B1 gene and its variants in prostate cancer. Dr. Sharifi explains that the adrenal permissive allele of HSD3B1 is common in people of European ancestry and is associated with increased conversion of adrenal androgen precursors to potent androgens like DHT. This allele is linked to faster progression and higher prostate cancer-specific mor...
|
- Details
- Alicia Morgans discusses her diverse roles at Dana-Farber, where she primarily treats prostate cancer patients, guiding them through various stages of their disease. Beyond patient care, Dr. Morgans is actively involved in teaching, research, and as the Medical Director of the Survivorship Program, she extends her expertise to a wide range of cancer patients. Reflecting on her career, Dr. Morgans...
|
- Details
- Andrea Miyahira hosts a discussion with Veda Giri, Ayesha Shafi, and Claire Fletcher, members of the PCF Women in Science Forum Organizing Committee. The forum aims to build a strong network of women in prostate cancer research and address gender inequities in science. Key themes include negotiation strategies for women, with insights from law professor Stacy Lee; amplifying women's voices in rese...
|
- Details
- Gerhardt Attard discusses advancing the treatment of advanced hormone-sensitive prostate cancer through biological research. Dr. Attard's work focuses on two main areas: analyzing tumor samples from clinical trials to understand the biology driving cancer aggressiveness and identifying new therapeutic targets. He emphasizes the need for prognostic tests to tailor treatments, especially considering...
|
- Details
- Zach Klaassen speaks with Dan George about a key study comparing Enzalutamide (Enza) and Abiraterone (Abi) in pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). This study addresses a significant gap in head-to-head clinical trials for these drugs. Dr. George discusses various data sources, including the French National Database, Flatiron, and VA data, all indicating a survi...
|
- Details
- Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI designated cooperative groups. The trial focuses on patients with biochemical recurrence after prostatectomy, examining the impact of PET scans on treatment decisions. It categorizes patients based on PET scan results: those without detectable cancer outside the pelvis...
|
- Details
- Alicia Morgans and Rana McKay delve into the complexities of treatment sequencing for metastatic castration-resistant prostate cancer. They highlight the expansive range of available therapies, including hormonal, targeted, immunotherapies, chemotherapy, and radioligand therapies. The focus is on the importance of patient involvement in decision-making, considering individual preferences, lifestyl...
|
- Details
- Zach Klaassen hosts Michael Hofman and Renu Eapen to discuss the LuTectomy trial, published in European Urology. The trial explores the use of Lutetium-PSMA-617 as a neoadjuvant treatment in prostate cancer surgery. Initially, the trial included both radiation and surgical arms, but later focused solely on the surgical approach. The study enrolled high-risk prostate cancer patients, with 20 partic...
|
- Details
- Jindan Yu shares her journey from a medical student in China to a leading researcher in prostate cancer in the US, emphasizing her passion for physics and math which led her to biomedical engineering and eventually to cancer genomics and epigenomics. She reflects on her recent move to Emory University, motivated by a desire for new challenges and opportunities to mentor others. Dr. Yu candidly dis...
|
- Details
- In a discussion with Alicia Morgans, Oliver Sartor delves into the innovative PSMAfore trial, focusing on treating metastatic CRPC in taxane-naive patients using PSMA PET-positive lesions. This trial, evolving from the VISION trial, aims to expand treatment eligibility by initiating therapy before chemotherapy, addressing the fact that nearly half of metastatic prostate cancer patients never recei...
|
